Medical/Pharmaceuticals

Antengene Announces First Patient Dosed in Phase II Trial of ATG-008 (Onatasertib) in Patients with Advanced Solid Tumors with Specific Genetic Alterations

SHANGHAI and HONG KONG, April 12, 2021 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and onco...

2021-04-12 08:00 2808

Hummingbird Bioscience Presents Pre-Clinical Data on its Next-Generation BCMA-TACI Dual-Specific T Cell Engager at 2021 AACR Annual Meeting

SINGAPORE, April 10, 2021 /PRNewswire/ -- Hummingbird Bioscience, an innovative clinical-stage biotech company focused on developing precision therapies against hard-to-drug targets to improve treatment outcomes, today announced that the company will be presentingpre-clinical data on its BCMA-TAC...

2021-04-10 12:01 3984

Copan, putting Covid-19 challenges behind and setting up for the post-pandemic scenario

BRESCIA, Italy, April 10, 2021 /PRNewswire/ -- With an email to the main distributors, Copan group's CEO describes how the ramp-up of Covid-19-related products has been concluded, and how the company is now reorganizing to face post-pandemic challenges.

2021-04-10 01:43 4365

RedHill Biopharma's Phase 2/3 COVID-19 Study of Opaganib Passes Fourth DSMB Review with Unanimous Recommendation to Continue

Independent Data Safety Monitoring Board unanimously recommends continuation of the global Phase 2/3 study of orally-administered opaganib in severe COVID-19 pneumonia based on review of unblinded safety data from the first 255 treated patients The 464-patient global Phase 2/3 COVID-19 study is ...

2021-04-09 19:00 4873

CDD Awarded $1.5M Phase 2 SBIR Grant on an Intelligent Chemical Structure Browser for Drug Discovery and Optimization

BURLINGAME, Calif., April 9, 2021 /PRNewswire/ -- Collaborative Drug Discovery, provider ofCDD Vault web-based drug discovery informatics platform, announced they won a competitive, peer-reviewed Phase 2 SBIR grant from NIH NCATS, titled: "Intelligent Chemical Structure Browser for Drug Discovery...

2021-04-09 18:57 1814

Everest Medicines Announces that Licensing Partner Gilead Sciences, Inc. has Received Full US FDA Approval of Trodelvy® for the Treatment of Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

SHANGHAI, April 9, 2021 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients inGreater C...

2021-04-09 08:30 5879

Seegene supports Mexico's 'back to school' campaign with COVID-19 tests and face masks

SEOUL, South Korea, April 9, 2021 /PRNewswire/ -- South Korea's leading molecular diagnostics firm Seegene Inc. (KQ096530) said Friday it is supporting the Mexican government's push to return life to pre-pandemic days. Durin...

2021-04-09 04:08 1987

Shanghai Genechem Co., Ltd. (Genechem) Announces appointment of Dr. Eric Rowinsky and Dr. Manuel Hidalgo to Scientific Advisory board, and abstract presentation at AACR 2021 on Claudin 6 Ab and K-Ras TCR-T

SHANGHAI, April 8, 2021 /PRNewswire/ -- Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel target discovery and development of novel therapeutics, today announced the appointment of Dr.Eric Rowinsky, President and Executive Chairman of the Board of Rgenix, Inc., and Dr...

2021-04-08 22:00 13689

CanSinoBIO Announces Approval for its Single-Dose COVID-19 Vaccine Convidecia™ in Chile

* Marks vaccine's first approval in South America, following Mexico, Pakistan, China and Hungary * Safe, stable storage and transportation between 2°C and 8°C, accessible by under-developed regions * 95.47% effective overall in preventing severe COVID-19 diseases 14 days after vaccination TI...

2021-04-08 21:17 7223

Lunit will participate in a Groundbreaking Prospective Study to Validate AI Performance

* A research team at the Karolinska Institutet in Sweden will assess the performance of AI startup Lunit's breast cancer AI software as an independent mammography reader in screening * The prospective study marks first of its kind, aiming to screen 55,000 women with mammography at Capio Sankt...

2021-04-08 16:15 2162

SenseTime Receives CE Mark for its AI Medical Solution SenseCare- Chest DR Pro Diagnostic Software

HONG KONG, April 8, 2021 /PRNewswire/ -- SenseTime, the world-leading artificial intelligence (AI) company, announced that it has recently been granted CE mark approval for its AI medical solution SenseCare-Chest DR Pro. Leveraging SenseTime's cutting-edge AI technologies, the solution can quickl...

2021-04-08 15:00 2754

SenseTime Receives CE Mark for its AI Medical Solution SenseCare- Chest DR Pro Diagnostic Software

SINGAPORE, April 8, 2021 /PRNewswire/ -- SenseTime, the world-leading artificial intelligence (AI) company, announced that it has recently been granted CE mark approval for its AI medical solution SenseCare-Chest DR Pro. Leveraging SenseTime's cutting-edge AI technologies, the solution can quickl...

2021-04-08 15:00 2138

SenseTime Receives CE Mark for its AI Medical Solution SenseCare-Chest DR Pro Diagnostic Software

KUALA LUMPUR, Malaysia, April 8, 2021 /PRNewswire/ -- SenseTime, the world-leading artificial intelligence (AI) company, announced that it has recently been granted CE mark approval for its AI medical solution SenseCare-Chest DR Pro. Leveraging SenseTime's cutting-edge AI technologies, the solut...

2021-04-08 15:00 2689

SenseTime Receives CE Mark for its AI Medical Solution SenseCare-Chest DR Pro Diagnostic Software

BANGKOK, April 8, 2021 /PRNewswire/ -- SenseTime, the world-leading artificial intelligence (AI) company, announced that it has recently been granted CE mark approval for its AI medical solution SenseCare-Chest DR Pro. Leveraging SenseTime's cutting-edge AI technologies, the solution can quickly ...

2021-04-08 15:00 2459

EyeYon Medical Announces Innovative Medical Device Designation Granted For EndoArt® In China

TEL-AVIV, Israel, April 8, 2021 /PRNewswire/ -- EyeYon Medical, an Israeli start-up company developing a variety of ophthalmic products for vision-threatening conditions, announces today that EndoArt® was granted the Innovative Device Status byChina's Center for Medical Device Evaluation, the ar...

2021-04-08 08:00 2557

Inmagene R&D Team expands with two new senior members joining the Company

SAN DIEGO and SHANGHAI and HANGZHOU, China, April 7, 2021 /PRNewswire/ -- Inmagene Biopharmaceuticals ("Inmagene") today announced that Dr.Anbo Xiang and Dr.Qian Xu joined the company. As CMO (China) and Senior VP, Operations, Dr. Xiang will be responsible for clinical development, operations, an...

2021-04-07 09:00 17448

WuXi Biologics Successfully Completed Pre-License Inspection and Routine GMP Inspection by U.S. FDA

WUXI, China, April 7, 2021 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, today announced that it has successfully completed both a Pre-License Inspection (PLI) and a routine GMP inspection by the U.S. FDA (FDA). T...

2021-04-07 08:22 22543

EDDA Technology Announces US$150 Million Financing Round, led by Softbank Vision Fund 2, with OrbiMed Participation, to Advance Intelligent Robotic Solutions for Precision Surgery

SHANGHAI and SUZHOU, China, April 7, 2021 /PRNewswire/ -- EDDA Healthcare and Technology Holding Ltd. and its subsidiaries EDDA Technology (Shanghai) Ltd., EDDA Technology Medical Solutions (Suzhou) Ltd., and EDDA Technology, Inc ( Princeton, NJ, USA), (hereafter jointly referred to as EDDA Techno...

2021-04-07 07:00 39281

Shanghai Genechem Co., Ltd. (Genechem) Announces Global Collaboration on Bispecific Antibodies

SHANGHAI, April 6,, 2021 /PRNewswire/ -- Shanghai Genechem Co., Ltd. (Genechem), a discovery company dedicated to novel drug target discovery and development of novel therapeutics, today announced the execution of a global collaboration with I-Mab (Nasdaq: IMAB), a Nasdaq-listed global bioph...

2021-04-06 22:26 38490

Gan & Lee receives EMA orphan drug designation for Phase I drug candidate GLR2007 for the treatment of glioma

BEIJING, and BRIDGEWATER, N.J., April 6, 2021 /PRNewswire/ -- Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH), a global biopharmaceutical company, today announced that the European Medicine Agency (EMA) Committee for Orphan Medicinal Products ...

2021-04-06 20:53 3891
1 ... 294295296297298299300 ... 397

Week's Top Stories